These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
113 related articles for article (PubMed ID: 35866644)
1. Follow-up Schedule for Patients With Sentinel Node-negative Cutaneous Melanoma (The MELFO Study): An International Phase III Randomized Clinical Trial. Moncrieff MD; Bastiaannet E; Underwood B; Francken AB; Garioch J; Damude S; Heaton M; Deckers EA; Patel N; Hoekstra-Weebers JE; Hoekstra HJ Ann Surg; 2022 Oct; 276(4):e208-e216. PubMed ID: 35866644 [TBL] [Abstract][Full Text] [Related]
2. The MelFo Study UK: Effects of a Reduced-Frequency, Stage-Adjusted Follow-Up Schedule for Cutaneous Melanoma 1B to 2C Patients After 3-Years. Moncrieff MD; Underwood B; Garioch JJ; Heaton M; Patel N; Bastiaannet E; Hoekstra-Weebers JEHM; Hoekstra HJ Ann Surg Oncol; 2020 Oct; 27(11):4109-4119. PubMed ID: 32623608 [TBL] [Abstract][Full Text] [Related]
3. The MELFO Study: A Multicenter, Prospective, Randomized Clinical Trial on the Effects of a Reduced Stage-Adjusted Follow-Up Schedule on Cutaneous Melanoma IB-IIC Patients-Results After 3 Years. Deckers EA; Hoekstra-Weebers JEHM; Damude S; Francken AB; Ter Meulen S; Bastiaannet E; Hoekstra HJ Ann Surg Oncol; 2020 May; 27(5):1407-1417. PubMed ID: 31535302 [TBL] [Abstract][Full Text] [Related]
4. Final Results of the Sunbelt Melanoma Trial: A Multi-Institutional Prospective Randomized Phase III Study Evaluating the Role of Adjuvant High-Dose Interferon Alfa-2b and Completion Lymph Node Dissection for Patients Staged by Sentinel Lymph Node Biopsy. McMasters KM; Egger ME; Edwards MJ; Ross MI; Reintgen DS; Noyes RD; Martin RC; Goydos JS; Beitsch PD; Urist MM; Ariyan S; Sussman JJ; Davidson BS; Gershenwald JE; Hagendoorn LJ; Stromberg AJ; Scoggins CR J Clin Oncol; 2016 Apr; 34(10):1079-86. PubMed ID: 26858331 [TBL] [Abstract][Full Text] [Related]
5. The MELFO-Study: Prospective, Randomized, Clinical Trial for the Evaluation of a Stage-adjusted Reduced Follow-up Schedule in Cutaneous Melanoma Patients-Results after 1 Year. Damude S; Hoekstra-Weebers JE; Francken AB; Ter Meulen S; Bastiaannet E; Hoekstra HJ Ann Surg Oncol; 2016 Sep; 23(9):2762-71. PubMed ID: 27194552 [TBL] [Abstract][Full Text] [Related]
6. Sentinel node biopsy for early-stage melanoma: accuracy and morbidity in MSLT-I, an international multicenter trial. Morton DL; Cochran AJ; Thompson JF; Elashoff R; Essner R; Glass EC; Mozzillo N; Nieweg OE; Roses DF; Hoekstra HJ; Karakousis CP; Reintgen DS; Coventry BJ; Wang HJ; Ann Surg; 2005 Sep; 242(3):302-11; discussion 311-3. PubMed ID: 16135917 [TBL] [Abstract][Full Text] [Related]
7. Patterns of initial recurrence and prognosis after sentinel lymph node biopsy and selective lymphadenectomy for melanoma. Wagner JD; Ranieri J; Evdokimow DZ; Logan T; Chuang TY; Johnson CS; Jung SH; Wenck S; Coleman JJ Plast Reconstr Surg; 2003 Aug; 112(2):486-97. PubMed ID: 12900606 [TBL] [Abstract][Full Text] [Related]
8. Sentinel node biopsy status is strongly predictive of survival in cutaneous melanoma: Extended follow-up of Oxford patients from 1998 to 2014. Thomson DR; Rughani MG; Kuo R; Cassell OCS J Plast Reconstr Aesthet Surg; 2017 Oct; 70(10):1397-1403. PubMed ID: 28625757 [TBL] [Abstract][Full Text] [Related]
15. Cervical sentinel lymph node biopsy for melanomas of the head and neck and upper thorax. Wagner JD; Park HM; Coleman JJ; Love C; Hayes JT Arch Otolaryngol Head Neck Surg; 2000 Mar; 126(3):313-21. PubMed ID: 10722003 [TBL] [Abstract][Full Text] [Related]
16. Sentinel node biopsy provides more accurate staging than elective lymph node dissection in patients with cutaneous melanoma. Doubrovsky A; De Wilt JH; Scolyer RA; McCarthy WH; Thompson JF Ann Surg Oncol; 2004 Sep; 11(9):829-36. PubMed ID: 15313732 [TBL] [Abstract][Full Text] [Related]
17. Adjuvant therapy of malignant melanoma and the role of sentinel node mapping. Eggermont AM Recent Results Cancer Res; 2000; 157():178-89. PubMed ID: 10857171 [TBL] [Abstract][Full Text] [Related]
18. Active surveillance of patients who have sentinel node positive melanoma: An international, multi-institution evaluation of adoption and early outcomes after the Multicenter Selective Lymphadenectomy Trial II (MSLT-2). Broman KK; Hughes T; Dossett L; Sun J; Kirichenko D; Carr MJ; Sharma A; Bartlett EK; Nijhuis AAG; Thompson JF; Hieken TJ; Kottschade L; Downs J; Gyorki DE; Stahlie E; van Akkooi A; Ollila DW; Frank J; Song Y; Karakousis G; Moncrieff M; Nobes J; Vetto J; Han D; Farma JM; Deneve JL; Fleming MD; Perez MC; Lowe MC; Olofsson Bagge R; Mattsson J; Lee AY; Berman RS; Chai H; Kroon HM; Teras J; Teras RM; Farrow NE; Beasley G; Hui JYC; Been L; Kruijff S; Kim Y; Naqvi SMH; Sarnaik AA; Sondak VK; Zager JS Cancer; 2021 Jul; 127(13):2251-2261. PubMed ID: 33826754 [TBL] [Abstract][Full Text] [Related]
19. Long-term follow-up and survival of patients following a recurrence of melanoma after a negative sentinel lymph node biopsy result. Jones EL; Jones TS; Pearlman NW; Gao D; Stovall R; Gajdos C; Kounalakis N; Gonzalez R; Lewis KD; Robinson WA; McCarter MD JAMA Surg; 2013 May; 148(5):456-61. PubMed ID: 23325294 [TBL] [Abstract][Full Text] [Related]
20. Should Sentinel Lymph Node Biopsy Be Performed for All T1b Melanomas in the New 8 Egger ME; Stevenson M; Bhutiani N; Jordan AC; Scoggins CR; Philips P; Martin RC; McMasters KM J Am Coll Surg; 2019 Apr; 228(4):466-472. PubMed ID: 30660817 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]